Clinical trials: Cancer of Nasopharynx
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Brain Tumors, Central Nervous System Tumors
Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma
RATIONALE: Electroacupuncture may help to reduce or prevent delayed nausea and vomiting in patients treated with chemotherapy. PURPOSE: This randomized clinical trial is studying the effectiveness of electroacupuncture in…
- Conditions
- Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00040911
- Testing
- electroacupuncture therapy, quality-of-life assessment
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Children's Oncology Group
Head and Neck Cancer, Lung Cancer
Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Conditions
- Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006036
- Testing
- cisplatin, lurtotecan liposome
- Where
- 3 sites in Canada
- Volunteers
- 14 people
- Sponsor
- NCIC Clinical Trials Group
Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
This clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy [IMRT]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated…
- Conditions
- Nasopharyngeal Carcinoma, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IVA Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Cancer
- Trial name
- NCT06682442
- Testing
- Intensity-Modulated Radiation Therapy (IMRT), Radiographic Imaging, Biospecimen Collection
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of California, San Francisco
Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Nasopharynx
Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with stage IV or recurrent nasopharyngeal cancer.
- Conditions
- Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx
- Trial name
- NCT00454142
- Testing
- pazopanib hydrochloride, pharmacological study, computed tomography
- Where
- 3 sites in Singapore
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
Head and Neck Cancer
Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer
Participant with squamous cell cancer of head and neck are invited to participate in this study. In this study the investigators will be Inserting the gene for interleukin-12 into a person's cancer cells with the anticipation to…
- Trial name
- NCT00004070
- Testing
- IL-12
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent or Metastatic Nasopharyngeal Cancer
Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
This study was designed to compare the efficacy and safety of tislelizumab (BGB-A317) combined with gemcitabine plus cisplatin versus placebo combined with gemcitabine plus cisplatin as first-line treatment for recurrent or…
- Trial name
- RATIONALE-309 (NCT03924986)
- Testing
- Tislelizumab, Gemcitabine, Cisplatin
- Where
- 37 sites in China, Taiwan and 1 more
- Volunteers
- 263 people
- Sponsor
- BeiGene
Nasopharyngeal Carcinoma
Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma
The purpose of this clinical research project is to explore potential biomarkers and validate the predictive and prognostic value of molecular signature in nasopharyngeal carcinoma.
- Trial name
- NCT03025854
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Otolaryngological Disease, Artificial Intelligence
To Develop and Validate a Nasoendoscopic Intelligent Diagnostic System for Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) occurs at a high frequency in southern China, northern Africa, and Alaska, with a reported incidence of 30 cases per 100 000 in Guangdong Province.
- Trial name
- NCT04547673
- Testing
- rigid nasal endoscopes
- Where
- 3 sites in China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Head and Neck Squamous Cell Carcinoma, Malignant Head and Neck Tumors
A Lithium-containing Mouthwash Prevention and Treatment of Oral Mucositis and Dysgeusia in Patients Undergoing Radiotherapy
To evaluate the efficacy and safety of lithium-containing mouthwash for prevention and treatment of oral mucositis and dysgeusia in patients undergoing radiotherapy for malignant head and neck tumors.
- Trial name
- NCT06251050
- Testing
- lithium-containing mouthwash （Phase I）, Plcacebo mouthwash （Phase II）, lithium-containing mouthwash（Phase II）
- Where
- China
- Volunteers
- 175 people
- Sponsor
- West China Hospital
Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults
Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Tests that measure how much saliva is made, hearing, swallowing, voice function, and quality of life may improve the ability to plan treatment for patients with advanced head and neck cancer and may help doctors find…
- Conditions
- Head and Neck Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Oral Complications of Radiation Therapy, Radiation Toxicity
- Trial name
- NCT00415025
- Testing
- adjuvant therapy, management of therapy complications, quality-of-life assessment
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Nasopharyngeal Cancer
Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer
- Trial name
- NCT01312311
- Testing
- Docetaxel, Cisplatin
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- Samsung Medical Center
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Nasopharyngeal Cancinoma (NPC)
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma
This single-arm, phase 2 trial evaluates the efficacy and safety of de-escalated radiotherapy (restricted to the primary tumor, omitting prophylactic neck irradiation) combined with neoadjuvant and adjuvant toripalimab…
- Trial name
- PUPA (NCT07110558)
- Testing
- Without prophylactic neck irradiation, PD-1 antibody (Toripalimab), Cisplatin
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Study of DC-CIK to Treat NPC
Concurrent of radiotherapy and chemotherapy is the main treatment method for patients with nasopharyngeal carcinoma (NPC). However, Relapse remains the major cause of treatment failure.
- Trial name
- NCT01821495
- Testing
- DC-CIK, Dendritic and Cytokine-induced Killer Cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Carcinoma
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal…
- Trial name
- NCT05211232
- Testing
- Tislelizumab
- Where
- 4 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma
It is well established that HPV infection has a casual and is a prognostic factor in several cancer types, including oropharynx. We wish to examine if HPV infection has a prognostic significance in nasopharyngeal carcinoma.
- Trial name
- NCT04014738
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Squamous Cell Carcinoma of the Head and Neck
Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
This study involves another course of radiation (called re-irradiation) to the participant's tumor. The type of radiation is called stereotactic body radiation therapy (SBRT).
- Trial name
- NCT02158234
- Testing
- Cisplatin, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Nasopharyngeal Neoplasms
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
Among all the head and neck tumors, nasopharyngeal carcinoma (NPC) has a high tendency of recurrence and metastasis. For the advanced NPC patients, chemoradiotherapy is the main way of treatment.
- Trial name
- NCT02444949
- Testing
- endostar, intensity modulated radiation, cisplatin
- Volunteers
- 75 people
- Sponsor
- China Three Gorges University, Yichang, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.